Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Multiple Sclerosis

  Free Subscription


29.01.2024

1 BMC Neurol
1 Brain
1 J Neurol Neurosurg Psychiatry
1 Lancet Neurol
5 Mult Scler
1 Neurology
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BMC Neurol

  1. HABIBI MA, Yazdan Panah M, Vaheb S, Olfatifar M, et al
    Validity and reliability of the Persian version of Recce stigma scale in people with multiple sclerosis and its impact on quality of life.
    BMC Neurol. 2024;24:36.
    PubMed         Abstract available


    Brain

  2. LAZZAROTTO A, Hamzaoui M, Tonietto M, Dubessy AL, et al
    Time is myelin: early cortical myelin repair prevents atrophy and clinical progression in multiple sclerosis.
    Brain. 2024 Jan 24:awae024. doi: 10.1093.
    PubMed         Abstract available


    J Neurol Neurosurg Psychiatry

  3. SIGNORI A, Ponzano M, Kalincik T, Ozakbas S, et al
    Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry.
    J Neurol Neurosurg Psychiatry. 2024 Jan 19:jnnp-2023-332603.
    PubMed         Abstract available


    Lancet Neurol

  4. LAURSON-DOUBE J, Helme A, Nonino F, Piggott T, et al
    WHO considers multiple sclerosis treatments essential.
    Lancet Neurol. 2024;23:140.
    PubMed        


    Mult Scler

  5. HIRT J, Janiaud P, Dublin P, Nicoletti GJ, et al
    Use of pragmatic randomized trials in multiple sclerosis: A systematic overview.
    Mult Scler. 2024 Jan 22:13524585231221938. doi: 10.1177/13524585231221938.
    PubMed         Abstract available

  6. CAMERLINGO S, Rubinstein F, Celia Ysrraelit M, Correale J, et al
    Clinical impact of gender and age at onset on disease trajectory in primary progressive multiple sclerosis patients.
    Mult Scler. 2024 Jan 21:13524585231219138. doi: 10.1177/13524585231219138.
    PubMed         Abstract available

  7. JEANTIN L, Januel E, Labauge P, Maillart E, et al
    COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022.
    Mult Scler. 2024 Jan 21:13524585231218149. doi: 10.1177/13524585231218149.
    PubMed         Abstract available

  8. TENI FS, Machado A, Fink K, Gyllensten H, et al
    Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden.
    Mult Scler. 2024 Jan 19:13524585231225929. doi: 10.1177/13524585231225929.
    PubMed         Abstract available

  9. VIDAL-JORDANA A, Sastre-Garriga J, Tintore M, Rovira A, et al
    Optic nerve topography in multiple sclerosis diagnostic criteria: Existing knowledge and future directions.
    Mult Scler. 2024 Jan 19:13524585231225848. doi: 10.1177/13524585231225848.
    PubMed         Abstract available


    Neurology

  10. RADZIK AM, Amezcua L, Anderson A, Gilmore S, et al
    Disparities by Race in Pregnancy Care and Clinical Outcomes in Women With Multiple Sclerosis: A Diverse Multicenter Cohort.
    Neurology. 2024;102:e208100.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  11. SUTTER PA, Willis CM, Menoret A, Nicaise AM, et al
    Astrocytic TIMP-1 regulates production of Anastellin, an inhibitor of oligodendrocyte differentiation and FTY720 responses.
    Proc Natl Acad Sci U S A. 2024;121:e2306816121.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.